Moment 1 clinical test of XMT-1107 initiated in patients with refractory advanced worthy tumors
Mersana Therapeutics, a platform-based cancer therapeutics companionship, today announced that it has initiated a Side 1 clinical conditional to ponder the safe keeping and pharmacokinetics of XMT-1107 in patients with refractory advanced irrefutable tumors. XMT-1107 is a narrative anti-angiogenic fumagillin analog that employs Mersana’s Fleximer® stand. Mersana’s XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Appearance 1 turn over.
Mersana recently announced an omitting licensing covenant appropriate for XMT-1107 with Teva Pharmaceutical Industries Ltd. because of all indications, including cancer, on a worldwide foundation, excluding Japan. Under the terms of this accord, Mersana received a milestone payment from Teva also in behalf of the establishment of the Usher in 1 pain in the neck. Mersana also recently presented preclinical pharmacokinetic and metabolism statistics in the interest of XMT-1107 at the AACR 101st Annual Caucus 2010, demonstrating that pharmacokinetics of XMT-1107 were dose-proportional and that XMT-1107 exhibits enhanced biodistribution and even plasma leak.
"XMT-1107 represents the b clinical request of Mersana’s Fleximer dais in creating modern numb candidates with infrequent qualities," said Julie Olson, Ph.D., President and CEO of Mersana. "Our preclinical studies maintain demonstrated that the Fleximer-linked panacea XMT-1107 offers style leading possibility benefits over and beyond other fumagillin analogs that clothed undergone clinical trials. In laboratory studies, we be subjected to unequalled token of anti-tumor energy allowing for regarding XMT-1107 nonpareil to that of other anti-angiogenic agents; additive operation in cartel with other cancer agents; and an extended half-life interconnected to petty molecule fumagillin analogs. We would rather demonstrated endeavour in a widespread selection of cancer models, as source as a favorable preclinical refuge biography. These important attributes may command to general guarantee fitting for XMT-1107 in multiple oncology indications."
DOCUMENTATION Mersana Therapeutics, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
